Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Midazolam in Healthy Male Volunteers

Inclusion Criteria: * Healthy male subjects as determined by results of the screening * Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation * Age ≥ 18 and ≤ 55 years * BMI ≥ 18.5 and ≤ 29.9 kg/m2 Exclusion Criteria: * Any finding during the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance * Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic, hematological, oncological, or hormonal disorders * Surgery of gastrointestinal tract (except appendectomy) * Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders * Relevant history of orthostatic hypotension, fainting spells, or blackouts * Chronic or relevant acute infections * History of allergy/hypersensitivity (including drug allergy) considered relevant to the trial as judged by the investigator * Intake of drugs with a long half-life (greater than 24 hours) (less than 1 month prior to administration or during the trial) * Use of any drugs, which might influence the results of the trial (less than 10 days prior to study drug administration or expected during the trial) * Participation in another trial with an investigational drug (less than 2 months prior to administration or expected during trial) * Smoker (more than 10 cigarettes/day or more than 3 cigars/day or more than 3 pipes/day) * Alcohol abuse (more than 60 g of ethanol per day) * Drug abuse * Blood donation or loss greater than 400 mL (less than 1 month prior to administration or expected during the trial) * Clinically relevant laboratory abnormalities